

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 August 2022 (04.08.2022)



(10) International Publication Number
WO 2022/165218 A1

- (51) **International Patent Classification:**
A61K 35/30 (2015.01) *C12N 5/079* (2010.01)
- (21) **International Application Number:**
PCT/US2022/014373
- (22) **International Filing Date:**
28 January 2022 (28.01.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/142,935 28 January 2021 (28.01.2021) US
63/182,760 30 April 2021 (30.04.2021) US
- (71) **Applicant: ASTERIAS BIOTHERAPEUTICS, INC.**
[US/US]; 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008 (US).
- (72) **Inventors; and**
- (73) **Applicants: ONISHI, Kento** [US/US]; c/o 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008 (US). **MANLEY, Nathan, C.** [US/US]; c/o 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008 (US). **HALBERSTADT, Craig, R.** [US/US]; c/o 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008 (US). **WHITELEY, Erik, M.** [US/US]; c/o 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008 (US). **BINETTE, Francois** [CA/US]; c/o 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008 (US). **SKALITER, Rami** [IL/IL]; c/o 2173 Salk Avenue, Suite 200, Carlsbad, CA 92008 (US).
- (74) **Agent: BELT, Caroline, D.** et al.; Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** COMPOSITIONS AND METHODS FOR TREATING SPINAL CORD INJURIES

Figure 1. Phase 1 Clinical Trial Study Schema.




Fig. 1

(57) **Abstract:** Provided herein are methods, compositions of matter, and devices for treating neurological diseases and illnesses, including spinal cord injury.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*